January 21, 2022 - This drug interaction tool from Pfizer provides information regarding potential drug interactions with PAXLOVID.
Each ListServ LIVE can be accessed by following the links below.
August 24, 2021 - Listserv LIVE #7: Revisiting Clinical and Operational Opportunities for mAb Therapies
Watch ListServ LIVE #7
March 31, 2021 - Listserv LIVE #4 : An Update on Oral Therapies for Early COVID-19
February 17, 2021 - Listserv LIVE #3: mAb Antibody Infusions in Urgent Care
State public health departments will receive
initial allocations for new oral therapies, and they will lead respective
distribution plans. To ensure your center will have access, register as a
"Provider", and join the Health Partner Ordering Portal (HPOP).
READ THE FACT SHEET.
EMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID -
EMERGENCY USE AUTHORIZATION (EUA) OF MOLNUPIRAVIR -
EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTMTM (casirivimab and imdevimab) -
EMERGENCY USE AUTHORIZATION (EUA) OF SOTROVIMAB -
COVID-19 Monoclonal Antibody Therapeutics Direct Order Process Fact Sheet -
COVID-19 Monoclonal Antibody Therapeutics Key Resources for Providers Fact Sheet -
COVID19 Monoclonal Therapeutics UCA Letter to Members -
Eligibility Criteria for mAb Infusion for COVID-19 Infection -
CMS Coverage of mAb Therapies -
CMS Pay Rates
Uninsured Patient Payment Policy
This message is from the UCA COVID-19 LISTSERV where UCA members can voice their opinions and share information. The opinions expressed are those of the individual and not necessarily those of the Urgent Care Association. For current guidelines and information always refer to the CDC coronavirus information page and your local health department.
Not a member? Individuals join now. | Vendors - interested in becoming a member? Join now.
August 4, 2022 - UCAccess Newsletter - UCA's Summer of Learning
June 22, 2022 - Urgent Caring Newsletter